Forbion’s New Fund
This article was originally published in Start Up
Executive Summary
Dutch venture capital firm, Forbion Capital Partners, has launched a new €92 milion ($116 million) life science fund to invest in 12 to 15 new companies. This is first close for the new fund called Forbion Capital Fund III, en route to a target of €150 to €200 million.
You may also be interested in...
Medtech: Assessing Potential Return On Investment
Medtech entrepreneurs and investors are awakening to a new reality in venture funding, where exit times are lengthening and returns on investment are falling short. At the recent IN3 meeting in Dublin, a panel of medtech investors discussed how they are adapting their investment strategies to this changing landscape.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.